Review articleA systematic review of the antifungal effectiveness and tolerability of amphotericin B formulations
References (53)
- et al.
Lipid-based amphotericin B: A review of the last 10 years of use
Int J Antimicrob Agents
(2001) Do variations in molecular structure affect the clinical efficacy and safety of lipid-based amphotericin B preparations?
Leuk Res
(1997)Management of fungal infections in neutropenic patients: More doubts than certainties?
Int J Antimicrob Agents
(2000)- et al.
Improving the quality of reports of meta-analyses of randomised controlled trials: The QUOROM statement. Quality of Reporting of Meta-analyses
Lancet
(1999) - et al.
Renal effects of amphotericin B lipid complex
Am J Kidney Dis
(1998) - et al.
Correlates of acute renal failure in patients receiving parenteral amphotericin B
Kidney Int.
(2001) - et al.
Risk factors for amphotericin B-associated nephrotoxicity
Am J Med.
(1989) - et al.
Review of comparative studies between conventional and liposomal amphotericin B (Ambisome) in neutropenic patients with fever of unknown origin and patients with systemic mycosis
Mycoses
(2000) - et al.
Amphotericin B Lipid Complex (ABLC) treatment in children with invasive fungal infections
- et al.
Invasive fungal infections in liver transplant recipients receiving tacrolimus as the primary immunosuppressive agent
Clin Infect Dis
(1997)
Lipid formulations of amphotericin B: Clinical efficacy and toxicities
Clin Infect Dis
Epidemiology and therapy of mycotic infections in immunocompromised host with special regard to the role of lipid formulations of amphotericin B [in Italian]
Recenti Prog Med
Amphotericin B lipid soluble formulations vs amphotericin B in cancer patients with neutropenia
Cochrane Database Syst Rev
Finding studies for systematic reviews: A basic checklist for researchers
Undertaking Systematic Reviews of Research on Effectiveness: CRD's Guidance for Those Carrying Out or Commissioning Reviews
The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions
J Epidemiol Community Health
A randomized comparison of liposomal versus conventional amphotericin B for the treatmetn of pyrexia of unknown origin in neutropenic patients
Br J Haematol.
Amphotericin B lipid complex compared with amphotericin B in the treatment of cyrptococcal meningitis in patients with AIDS
Clin Infect Dis.
Bias in meta-analysis detected by a simple, graphical test
BMJ
Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group
N Engl J Med.
Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia
Clin Infect Dis
Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections
Br J Haematol
Liposomal amphotericin B (AmBisome) compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitis
AIDS
Cited by (161)
Current development of a lipid-based nanocochleates containing Amphotericin B for oral administration
2024, Journal of Drug Delivery Science and TechnologyAmphotericin-Associated Infusion-Related Reactions: A Narrative Review of Pre-Medications
2021, Clinical TherapeuticsCitation Excerpt :When amphotericin B deoxycholate was compared to lipid formulations of amphotericin B in individual studies, there were fewer IRAEs after liposomal amphotericin B administration,28,35 but similar rates of IRAEs after amphotericin B lipid complex administration.27,35 However, a meta-analysis comparing a lipid formulation of amphotericin B and amphotericin B deoxycholate did not report a significant difference in the risks for IRAEs, irrespective of pre-medications.26 Nonetheless, IRAEs occur among patients who received pre-medications15,16 and regardless of the duration of infusion.18–20
Chemical composition and antibacterial effect of ethanolic extract of Buxus sempervirens on cryogenic strains of microorganisms in vitro
2020, Chemical Data CollectionsCitation Excerpt :For over 50 years amphotericinin has been an effective preparation against a broad spectrum of systemic fungal diseases. It is usually used as a standard during the search for new substances which have activity against fungi of the Candida genus [25]. The two preparations used are the basic means used in Ukraine for control of epizooitic strains of microorganisms in the treatment of animals.
Nephrotoxicity of Antimicrobials and Antibiotics
2020, Advances in Chronic Kidney DiseaseCitation Excerpt :The most important specific risk factor of kidney injury is the total amphotericin cumulative dose (>600 mg).48,49 Lipid-based amphotericin formulations, including amphotericin B lipid complex and liposomal amphotericin B, achieve considerably less plasma and renal concentration, reduced nephrotoxicity (odds ratio 0.42, 95% CI 0.33-0.54), and overall mortality (odds ratio 0.72, 95% CI 0.33-0.54).50 Lipid-based products are substantially more expensive; however, the overall cost of amphotericin B deoxycholate-induced nephrotoxicity is higher than lipid-based amphotericin treatment cost.51
Ligand density on nanoparticles: A parameter with critical impact on nanomedicine
2019, Advanced Drug Delivery Reviews
- ∗
This work was carried out independently of The Audit Commission. The views expressed here represent those of the author alone.